Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Polaryx Therapeutics, Inc. on September 10, 2026. The company is an emerging growth company incorporated in Nevada, with its principal executive offices in Paramus, NJ. Its common stock trades on The Nasdaq Capital Market under the symbol PLYX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.
Material Changes
No material financial changes are reported in this filing. The primary events are the election of directors and the ratification of the independent auditor.
Guidance, Outlook, and Voting Results
The filing details the outcomes of two proposals voted on at the Annual Meeting:
- Election of Class I Directors: Alex Yang and Mitchel Berger were elected. Each received 30,072,137 votes cast for, with 332 votes withheld and 472,610 broker non-votes. They will serve until the 2029 annual meeting.
- Ratification of Independent Auditor: The appointment of Grant Thornton LLP for the fiscal year ending December 31, 2026, was approved. The vote count was 30,510,106 in favor, 34,973 against, with no abstentions or broker non-votes.
The filing does not contain management commentary on future guidance, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the full text of the Proxy Statement filed on July 28, 2026, for detailed background on the director nominees and auditor appointment.
- Confirm the total number of shares outstanding to contextualize the voting percentages.
- Review subsequent filings for the company's financial results for the period ending December 31, 2026, as this 8-K contains no financial data.